Investor/Share Issue 2025
INVITATION TO SUBSCRIPTION
Diagonal Bio is currently carrying out a rights issue of units, with a subscription period from 23 January until 6 February 2025. In parallel, a directed issue to the same terms is being conducted to trotting trainer Daniel Redén and Svea Bank AB. The motive for the transaction is to focus on validation of LAMPlify®‘s commercial interest within the equine healthcare sector. The transaction will, upon full subscription in the rights issue, provide Diagonal Bio with a total of approximately SEK 7.7 million before deduction of issue related costs and the issue proceeds are intended to be used for:
Through the rights issue, warrants of series TO 2 are issued. The warrants have an exercise period in June 2025 and can provide the company with an additional SEK 3.4 million. Each warrant of series TO 2 gives the holder the right to subscribe for one new share in Diagonal Bio to the exercise price of SEK 0.01 per share.
It is the Board’s assessment that the net proceeds from the directed issue, a fully subscribed rights issue as well as fully exercised warrants series TO 2 will fund the company’s operations until January 2026.
Kalqyl
To subscribe for units in the rights issue, please contact your bank or the issuing agent Aqurat Fondkommission AB. Links to Avanza, Nordnet and Aqurat are available below.
Avanza: Övriga erbjudanden
Nordnet: Företagshändelser och IPO:er | Nordnet
Aqurat: Diagonal Bio AB – Aqurat Fondkommission AB
Karin Wehlin
CEO, Diagonal Bio
Medicon Village, Lund
Phone: +46 (0)70 305 24 88
kw@diagonalbio.com